Richard Brand, MBA is the CFO of DiaCarta, a precision molecular diagnostics company developing liquid biopsy tests and COVID-19 diagnostic tests. Prior to his position at DiaCarta, Richard helped raise $86 million as CFO for a private diagnostics company, Laboratory for Advanced Medicine, Inc. He has decades of experience in the financial and life science industries that he uses to aid in DiaCarta’s mission of advancing cancer care. Richard holds a Bachelor of Arts in Economics and English from the University of Iowa and received his MBA from the University of Chicago Booth School of Business.
The Federal Trade Commission and the European Union are reviewing the soundness of this acquisition. But if Illumina acquires Grail, the company that it spawned back in January 2016, will it squeeze the nascent liquid biopsy market?